If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
=== In silico screening === T cell epitope content, which is one of the factors that contributes to the risk of immunogenicity can now be measured relatively accurately using in silico tools. Immunoinformatics algorithms for identifying T-cell epitopes are now being applied to triage protein therapeutics into higher risk and low risk categories. These categories refer to assessing and analyzing whether an immunotherapy or vaccine will cause unwanted immunogenicity. One approach is to parse protein sequences into overlapping nonamer (that is, 9 amino acid) peptide frames, each of which is then evaluated for binding potential to each of six common class I HLA alleles that "cover" the genetic backgrounds of most humans worldwide. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein's overall "immunogenicity score". In addition, sub-regions of densely packed high scoring frames or "clusters" of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. Using this approach, the clinical immunogenicity of a novel protein therapeutics can be calculated. Consequently, a number of biotech companies have integrated in silico immunogenicity into their pre-clinical process as they develop new protein drugs.
== Production == The novel was partly inspired by Stephenson's involvement with the Clock of the Long Now project, to which he contributed three pages of sketches and notes. A separate compact disc, entitled IOLET: Music from the World of Anathem, containing eight experimental vocal compositions by David Stutz, was sold separately through CD Baby and the Long Now Foundation, with profits going to The Clock of the Long Now project. To create the world of Arbre, Stephenson constructs new vocabulary. In order to familiarize the reader with the new words, many of which are analogous to English, Latin or Greek words and ideas, a glossary is included at the end of the book. Each chapter begins with a definition of one of these words, which usually relates to the chapter in some way. In addition, the Orth language spoken by the characters was created by Jeremy Bornstein at the author's request, and has been documented. The word anathem was invented by Stephenson, based on the word anthem and the Greek word anathema. In the book, an anathem is a mathic ritual by which one is expelled from the mathic world.
According to data from 2024, the 250 seats in the People's Council are distributed as follows: Sunni Muslims (171 seats), reflecting their majority status in Syria's population, Alawites (39 seats), corresponding to their demographic proportion, Christians (23 seats), allocated across various provinces, Druze (9 seats), with a significant number from the Suwayda Governorate, Shia Muslims (5 seats), Ismailis (2 seats) and Murshidites (1 seat). Out of a 210-member People's Assembly formed after the fall of the Ba'athist government in 2024, 140 seats were allocated through a transitional electoral process. Of those elected, six were women and 10 were minority representatives (Kurds, Christians, and two Alawites). The 70 appointed members included 15 women, with officials stating the appointments were intended to address limited representation in the elected portion of the assembly.
In February 2015, the FDA reported about a transmission risk when people undergo a gastroenterology procedure called endoscopic retrograde cholangiopancreatography, where an endoscope enters the mouth, passes the stomach, and ends in the duodenum; if incompletely disinfected, the device can transmit CRE from one patient to another. The FDA's safety communication came a day after the UCLA Health System, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015. The FDA had issued its first notice about the devices in 2009.
== Therapeutic use == Though the exact mechanism of its anti-epilepsy effect is not clear, several studies have shown that BmKAEP can inhibit coriaria lactone-induced epilepsy in rats by prolonging the latent epilepsy period, relieving the degree of seizures and shortening its average duration, at a pharmacological dosage of only 0.057 μg/g. Mesobuthus martensii, especially its tail, has been used in Chinese traditional medicine to treat several neuronal diseases, such as several types of paralysis, apoplexy and epilepsy.
Sources: en.wikipedia.org
=== Cited texts === Dhillon, Karminder Singh (2009). Malaysian Foreign Policy in the Mahathir Era 1981–2003: Dilemmas of Development. NUS Press. ISBN 978-9971-69-399-2. Milne, R. S.; Mauzy, Diane K. (1999). Malaysian Politics under Mahathir. Routledge. ISBN 0-415-17143-1. Morais, J. Victor (1982). Mahathir: A Profile in Courage. Eastern Universities Press. OCLC 8687329. Sankaran, Ramanathan; Mohd Hamdan Adnan (1988). Malaysia's 1986 General Election: the Urban-Rural Dichotomy. Institute of Southeast Asian Studies. ISBN 981-3035-12-9. Stewart, Ian (2003). The Mahathir Legacy: a Nation Divided, a Region at Risk. Allen & Unwin. ISBN 1-86508-977-X. Wain, Barry (2010). Malaysian Maverick: Mahathir Mohamad in Turbulent Times. Palgrave Macmillan. ISBN 978-0-230-23873-2. James Chin & Joern Dosch. Malaysia Post Mahathir: a decade of change?. Marshall Cavendish. 2016. ISBN 9814677558
He was sceptical of organised religion, referring to himself as a sceptic and an agnostic with "a strong inclination towards atheism". In 1960, Crick accepted an honorary fellowship at Churchill College, Cambridge, one factor being that the new college did not have a chapel. Some time later a large donation was made to establish a chapel and the College Council decided to accept it. Crick resigned his fellowship in protest. In October 1969, Crick participated in a celebration of the 100th year of the journal Nature in which he attempted to make some predictions about what the next 30 years would hold for molecular biology. His speculations were later published in Nature. Near the end of the article, Crick briefly mentioned the search for life on other planets, but he held little hope that extraterrestrial life would be found by the year 2000. He also discussed what he described as a possible new direction for research, what he called "biochemical theology". Crick wrote "so many people pray that one finds it hard to believe that they do not get some satisfaction from it". A field similar to Crick's hypothesised "biochemical theology" now exists as neurotheology. Crick suggested that it might be possible to find chemical changes in the brain that were molecular correlates of the act of prayer. He speculated that there might be a detectable change in the level of some neurotransmitter or neurohormone when people pray.
This is combined with exposure control to tailor the effect to represent the human eye. For example, as the player exits a dark area into a light area, the new area is initially glaringly bright, but quickly darkens, representing the adjustment of the player character's eyes to the light. New cube mapping techniques allow the reflection cast by an object to correspond with the brightness of the light source, and lightmaps enable light bouncing and global illumination to be taken into account in the rendering. Refraction effects were added to make light account for the physical attributes of an object and to emulate the way light is reflected by water. The Lost Coast level is specifically designed to showcase these effects. It uses the sea and beach as opportunities to demonstrate water-based effects, the monastery to demonstrate bloom from its whitewash walls, and the sanctuary to provide the means to show refraction through stained glass windows and cube maps on golden urns and candlesticks. As a technology showcase, Valve considered Lost Coast to have very demanding system requirements. The game runs on computers with specifications lower than what is recommended, albeit without some key features such as high dynamic range. If a non-high-dynamic-range-capable card is used, the developer commentary is changed slightly to reflect this. For example, Valve president Gabe Newell would describe the effects that are seen differently.
=== Sublingual administration === Estradiol tablets can be taken sublingually instead of orally. Non-micronized estradiol tablets in doses of 0.125, 0.25, and 1 mg were previously marketed for use by sublingual administration under brand names such as Diogynets, Estradiol Membrettes, and Dimenformon in the 1950s. Non-micronized estradiol has poor water solubility, but micronized estradiol is rapidly absorbed by the sublingual route. All oral estradiol tablets are micronized, as this improves the efficiency of estradiol absorption in the gastrointestinal tract. Likewise, all oral estradiol valerate tablets seem to be micronized. The sublingual route is, in actuality, probably a combination of sublingual and oral delivery of estradiol due to incidental swallowing of some of the estradiol. The absorption of sublingual estradiol can be attributed to the rich vascularization under the tongue. With administration of an oral estradiol tablet sublingually, complete dissolution of the tablet occurs within a few minutes and circulating levels of estradiol begin to rise within 5 minutes. Maximal levels of estradiol occur after 30 to 60 minutes of administration. After this, estradiol levels drop steeply within 4 hours, and this is followed by a more gradual decline in levels of estradiol and a return to baseline concentrations by 24 hours. The rapid rise and steep fall of estradiol levels with sublingual administration of estradiol is analogous to the case of intravenous injection and intranasal administration of the hormone.
In congenital adrenal hyperplasia (CAH) due to deficiency of 21-hydroxylase or cytochrome P450 oxidoreductase (POR), the associated elevated 17OHP levels result in flux through the backdoor pathway to DHT that begins with 5α-reduction of 17OHP. This pathway may be activated regardless of age and sex and cause symptoms of androgen excess. In adult females, excess androgens can cause hirsutism (excessive hair growth), alopecia (hair loss), menstrual irregularities, infertility, and polycystic ovarian syndrome. In adult males, excess androgens can cause prostate enlargement, prostate cancer, and reduced sperm quality. In adults of both sexes, excess androgens can also cause metabolic disturbances, such as insulin resistance, dyslipidemia, hypertension, and cardiovascular disease. In fetus, excess of androgens due to excess of fetal 17OHP in CAH may contribute to DHT synthesis that leads to external genital virilization in newborn girls with CAH. P4 levels may also be elevated in CAH, leading to androgen excess via the backdoor pathway from P4 to DHT. 17OHP and P4 may also be substrates for 11-oxygenated androgens in CAH. Masculinization of female external genitalia in a fetus due to the mother's intake of certain exogenous hormones—the so-called progestin-induced virilization—is usually less noticeable than in congenital adrenal hyperplasia (CAH), and unlike CAH, it does not cause progressive virilization.
Sources: en.wikipedia.org
This problem is made worse if anticoagulants such as heparin or citrate are used. The anticoagulant that causes the least problems is EDTA. Romanowsky stain or a variant stain is usually used. Some laboratories mistakenly use the same staining pH as they do for routine haematology blood films (pH 6.8): malaria blood films must be stained at pH 7.2, or Schüffner's dots and James' dots will not be seen. Immunochromatographic capture procedures (rapid diagnostic tests such as the malaria antigen detection tests) are nonmicroscopic diagnostic options for the laboratory that may not have appropriate microscopy expertise available.
== Reaction == In native chemical ligation, the ionized thiol group of an N-terminal cysteine residue of an unprotected peptide attacks the C-terminal thioester of a second unprotected peptide, in an aqueous buffer at pH 7.0 and room temperature. This transthioesterification step is reversible in the presence of an aryl thiol catalyst, rendering the reaction both chemoselective and regioselective, and leads to formation of a thioester-linked intermediate. The intermediate rapidly and spontaneously rearranges by an intramolecular S,N-acyl shift that results in the formation of a native amide ('peptide') bond at the ligation site (scheme 1).
== External links == Elastin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Histology image: 21402loa – Histology Learning System at Boston University GeneReviews/NIH/NCBI/UW entry on Williams or Williams-Beuren Syndrome The Elastin Protein Microfibril This article incorporates text from the United States National Library of Medicine, which is in the public domain.
=== Vaccination === Although IAP for EOD prevention is associated with a large decline in disease incidence, there is no effective strategy for preventing late-onset neonatal GBS disease. Vaccination is considered an ideal means of preventing not only EOD and LOD but also GBS infections in adults at risk. The capsular polysaccharide of GBS is not only an important GBS virulence factor, but it is also an excellent candidate for the development of an effective vaccine. Protein-based vaccines are also in development. Nevertheless, though research and clinical trials for the development of an effective vaccine to prevent GBS infections are underway, no vaccine is available in 2026.
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, and in the European Union in January 2008.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.